Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Last week, stocks pushed to fresh highs as strong jobs data and gains in chip stocks helped lift the market. The S&P 500 (SPX) rose 0.84% to 7,397....

The Week That Was, The Week Ahead: Macro and Markets, May 10

Vanguard S&P 500 ETF ($VOO) remains one of the most popular choices for investors seeking broad exposure to the U.S. stock market. However, as mark...

Looking Beyond VOO? These 3 BlackRock ETFs Offer 20%+ Upside in 2026

Quantinuum, a quantum computing firm backed by industrial conglomerate Honeywell ($HON), has filed for a U.S. IPO as it looks to take advantage of ...

Honeywell-Backed Quantinuum Files for IPO amid Quantum Computing Excitement

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eton Pharmaceuticals (ETON), Amgen (AMGN) and Brig...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eton Pharmaceuticals (ETON), Amgen (AMGN) and BrightSpring Health Services, Inc. (BTSG)

In a report released yesterday, Vamil Divan from Guggenheim maintained a Hold rating on Amgen, with a price target of $340.00. According to TipRank...

Guggenheim Sticks to Their Hold Rating for Amgen (AMGN)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Amgen today and set a price target of $400.00. Seigerman covers the Healthcare sector...

Amgen (AMGN) Gets a Buy from BMO Capital

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN) and BridgeBio Pharma (BBIO) with bullis...

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), BridgeBio Pharma (BBIO)

In a report released yesterday, from Raymond James assigned a Hold rating to Amgen. The company’s shares closed yesterday at $329.82. Amgen has an ...

Raymond James Issues a Hold Rating on Amgen (AMGN)

Amgen Inc (($AMGN)) has held its Q1 earnings call. Read on for the main highlights of the call. Amgen’s latest earnings call struck a cautiously up...

Amgen Earnings Call Highlights Growth Engines, Tax Risk

J.P. Morgan analyst initiated coverage with a Hold rating on Amgen today and set a price target of $300.00. In addition to J.P. Morgan, Amgen also ...

Amgen (AMGN) Gets a Hold from J.P. Morgan

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN), Immunome (IMNM) and Resmed (RMD). Amgen (AMGN) RBC ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Immunome (IMNM) and Resmed (RMD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Dexcom (DXCM) and Merit Medical Syst...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Dexcom (DXCM) and Merit Medical Systems (MMSI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Alnylam Pharma (ALNY) and The Ensign...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and The Ensign Group (ENSG)

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Amgen today and set a price target of $307.00. Ahmad covers the Healthc...

Bank of America Securities Keeps Their Sell Rating on Amgen (AMGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Weave Communications (WEAV) and Orth...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Weave Communications (WEAV) and OrthoPediatrics (KIDS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN) and Icon (ICLR). Amgen (AMGN) In a report released y...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Icon (ICLR)

The U.S. Food and Drug Administration (FDA) is looking to deploy artificial intelligence to achieve real-time evaluation of clinical trial results ...

FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. This Amgen Inc. (AMGN) study, titled “Multicenter, Safety Follow-up Study to...

Amgen Tracks Long-Term Romosozumab Safety in Children: What Investors Should Know

Analysts are intrested in these 5 stocks: ( ($WHR) ), ( ($ULTA) ), ( ($OKTA) ), ( ($JPM) ) and ( ($AMGN) ). Here is a breakdown of their recent


Whirlpool, Ulta, Okta, JPMorgan, Amgen Trending With Analysts

Amgen ( ($AMGN) ) has issued an update. On April 22, 2026, Amgen announced that David M. Reese, M.D., executive vice president and chief technology...

Amgen Announces CTO Retirement and Strategic Leadership Realignment

Canaccord Genuity analyst initiated coverage with a Hold rating on Amgen yesterday and set a price target of $366.00. The company’s shares closed y...

Amgen (AMGN) Initiated with a Hold at Canaccord Genuity

Bernstein analyst Courtney Breen maintained a Hold rating on Amgen today and set a price target of $335.00. Breen covers the Healthcare sector, foc...

Current Quarter	$5.62	Next Quarter	$5.73
Current Year	$22.37	Next Year	$23.53
QoQ Growth	+2.0%	YoY Growth	+5.2%
3Y EPS CAGR	+5.6%	Target Price	$356.55
Consensus	Buy	Upside	+9.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMGN	$324.39	-0.59%	2.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMGN	$324.39	-0.6%	2.03M
3
4
5
6

AMGN

AMGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Amgen Inc. Data in Excel

Get Amgen Inc. Data in Excel